A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients-Reference-Cited by-同舟云学术

A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients

Published:2019-05-18 Issue:12 Volume:58 Page:1577-1593
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Moj Daniel,Maas Hugo,Schaeftlein André,Hanke Nina,Gómez-Mantilla José David,Lehr Thorsten^ORCID

Funder

Boehringer Ingelheim Pharma GmbH & Co. KG

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40262-019-00776-y.pdf

Reference76 articles.

1. Boehringer Ingelheim Pharmaceuticals Inc. Full prescribing information: Pradaxa, 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s024lbl.pdf . Accessed 29 Oct 2018.

2. Ishiguro N, Kishimoto W, Volz A, Ludwig-Schwellinger E, Ebner T, Schaefer O. Impact of endogenous esterase activity on in vitro p-glycoprotein profiling of dabigatran etexilate in caco-2 monolayers. Drug Metab Dispos. 2013;42:250–6. https://doi.org/10.1124/dmd.113.053561 .

3. Laizure SC, Parker RB, Herring VL, Hu Z-Y. Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis. Drug Metab Dispos. 2013;42:201–6. https://doi.org/10.1124/dmd.113.054353 .

4. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386–99. https://doi.org/10.1124/dmd.107.019083 .

5. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292–303. https://doi.org/10.1111/j.1365-2125.2007.02899.x .

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the relative contribution of CYP3A-and P-gp-mediated pathways to the overall disposition and drug-drug interaction of dabigatran etexilate using a comprehensive mechanistic physiological-based pharmacokinetic model;Frontiers in Pharmacology;2024-03-07

2. Membrane transporters in drug development and as determinants of precision medicine;Nature Reviews Drug Discovery;2024-01-24

3. Pharmacokinetics and pharmacodynamics of direct oral anticoagulants;Expert Opinion on Drug Metabolism & Toxicology;2023-11-24

4. Physiologically-Based Pharmacokinetic Modeling for Drugs Cleared by Non-Cytochrome P450 Enzymes: State-of-the-Art and Future Perspectives;Drug Metabolism and Disposition;2023-10-25

5. Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults;European Journal of Pharmaceutical Sciences;2023-03